Evidence mapPaperPMID 41303403Full record

ArticleInternational journal of molecular sciences2025

Atherogenic Dyslipidemia and Its Association with

Astrid Lorena Urbano Cano, Rosa Elvira Álvarez Rosero, Yamil Liscano

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Astrid Lorena Urbano CanoGrupo de Investigación en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia.
Rosa Elvira Álvarez RoseroGrupo de Investigación en Genética Humana Aplicada (GIGHA), Departamento de Ciencias Fisiológicas, Universidad del Cauca, Popayan 190003, Colombia.ORCID 0000-0001-6507-5984
Yamil LiscanoGrupo de Investigación en Salud Integral (GISI), Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia.ORCID 0000-0002-2674-8725

Funding

This research has been funded by the Direccion General de Investigaciones of Universidad Santiago de Cali, under Call No. DGI-01-2025. This research has been funded by the Direccion General de Investigaciones of Universidad Santiago de Cali, under Call No. DGI-01-2025.
6 · The paper itself

Abstract

Atherogenic dyslipidemia (AD) is a high-risk phenotype for cardiovascular disease, characterized by elevated triglycerides, increased small dense low-density lipoprotein cholesterol (sdLDL-C), and frequently coexisting hypertension. Although

Indexed as

Alpha-Ketoglutarate-Dependent Dioxygenase FTOAtherosclerosisDyslipidemiasGenetic Predisposition to DiseasePerimenopausePolymorphism, Single NucleotideAdultCase-Control StudiesCholesterol, LDLFemaleGene-Environment InteractionGenotypeHaplotypesHumansLinkage DisequilibriumMiddle AgedAlpha-Ketoglutarate-Dependent Dioxygenase FTOCholesterol, LDLFTO protein, humanTriglyceridesatherogenic dyslipidemiaFTOgenetic polymorphisms

Identifiers

PMID41303403
PMCPMC12652215

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.